131 related articles for article (PubMed ID: 22593469)
21. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.
Teramoto K; Asada Y; Ozaki Y; Suzumura Y; Nakano Y; Sawai S; Tezuka N; Inoue S; Fujino S
Cancer Chemother Pharmacol; 2012 Oct; 70(4):531-7. PubMed ID: 22864949
[TBL] [Abstract][Full Text] [Related]
23. [A feasible study of docetaxel/nedaplatin combined chemotherapy for relapsed or refractory esophageal cancer patients as a 2nd-line chemotherapy].
Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Urakami A; Yamashita K; Tsunoda T
Gan To Kagaku Ryoho; 2007 May; 34(5):725-8. PubMed ID: 17496445
[TBL] [Abstract][Full Text] [Related]
24. A phase II study of neoadjuvant and adjuvant chemotherapy with 5-fluorodeoxyuridine, leucovorin, oxaliplatin and docetaxel in the treatment of previously untreated advanced esophageal adenocarcinoma.
Solomon N; Mezentsev D; Reis I; Lima M; Rios J; Avisar E; Franceschi D; Livingstone A; Podolsky L; Ardalan B
Jpn J Clin Oncol; 2011 Apr; 41(4):469-76. PubMed ID: 21258083
[TBL] [Abstract][Full Text] [Related]
25. A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.
Miyazaki A; Kobayashi J; Yamamoto T; Kido Y; Takemura K; Abe M; Tomihara K; Dehari H; Nakamori K; Nagai I; Hiratsuka H
Oral Oncol; 2008 May; 44(5):471-6. PubMed ID: 17826308
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of docetaxel combined with nedaplatin for patients with recurrent and metastatic nasopharyngeal carcinoma.
Peng PJ; Lv BJ; Tang C; Liao H; Lin Z; Liu YM; Wang ZH; Wang SY; Cheng ZB
Drug Des Devel Ther; 2015; 9():6401-5. PubMed ID: 26677316
[TBL] [Abstract][Full Text] [Related]
27. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
[TBL] [Abstract][Full Text] [Related]
28. A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.
Sato Y; Takayama T; Sagawa T; Okamoto T; Miyanishi K; Sato T; Araki H; Iyama S; Abe S; Murase K; Takimoto R; Nagakura H; Hareyama M; Kato J; Niitsu Y
Cancer Chemother Pharmacol; 2006 Nov; 58(5):570-6. PubMed ID: 16463059
[TBL] [Abstract][Full Text] [Related]
29. [Nedaplatin and 5-fluorouracil combined with radiotherapy for advanced esophageal cancer].
Nakamura T; Ide H; Eguchi R; Hayashi K; Ota M; Narumiya K; Takasaki K; Mitsuhashi M
Gan To Kagaku Ryoho; 2003 Jun; 30(6):803-7. PubMed ID: 12852347
[TBL] [Abstract][Full Text] [Related]
30. A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.
Yamazaki K; Hironaka S; Boku N; Yasui H; Fukutomi A; Yoshino T; Onozawa Y; Hasuike N; Inui T; Yamaguchi Y; Ono H
Int J Clin Oncol; 2008 Apr; 13(2):150-5. PubMed ID: 18463960
[TBL] [Abstract][Full Text] [Related]
31. Retrospective analysis of 27 consecutive patients treated with docetaxel/nedaplatin combination therapy as a second-line regimen for advanced esophageal cancer.
Kanai M; Matsumoto S; Nishimura T; Shimada Y; Watanabe G; Kitano T; Misawa A; Ishiguro H; Yoshikawa K; Yanagihara K; Teramukai S; Mitsumori M; Chiba T; Sakai Y; Fukushima M
Int J Clin Oncol; 2007 Jun; 12(3):224-7. PubMed ID: 17566847
[TBL] [Abstract][Full Text] [Related]
32. [Prospective non-randomized study of chemotherapy combined with radiotherapy versus chemotherapy alone in patients with metastatic or relapsed esophageal squamous cell carcinoma].
Zhang XD; Shen L; Li J; Li Y; Li J; Zhang XT; Jin ML
Zhonghua Zhong Liu Za Zhi; 2007 Jun; 29(6):474-7. PubMed ID: 17974288
[TBL] [Abstract][Full Text] [Related]
33. [An elderly hemodialytic case of recurrent esophageal cancer given combination chemotherapy with docetaxel and nedaplatin who showed temporal relief of swallowing disturbance].
Miura T; Hosojima Y; Nakamura J; Yamada S; Nakazawa Y; Ozeki Y; Miura T; Yanagi M; Yamazaki H; Takahashi T
Gan To Kagaku Ryoho; 2010 May; 37(5):883-5. PubMed ID: 20495320
[TBL] [Abstract][Full Text] [Related]
34. [A case of esophageal carcinoma with multiple liver metastases successfully treated with nedaplatin (NDP) and 5-fluorouracil (5-FU) combined with radiotherapy].
Kaneko K; Ito H; Ito T; Konishi K; Kurahashi T; Yamamoto T; Eguchi J; Kitahara T; Mitamura K
Gan To Kagaku Ryoho; 2001 Jun; 28(6):831-4. PubMed ID: 11432353
[TBL] [Abstract][Full Text] [Related]
35. Salvage chemotherapy with paclitaxel, ifosfamide, and nedaplatin in patients with urothelial cancer who had received prior cisplatin-based therapy.
Shinohara N; Harabayashi T; Suzuki S; Nagao K; Seki H; Murakumo M; Mitsuhashi K; Demura T; Nagamori S; Matsuyama H; Naito K; Nonomura K
Cancer Chemother Pharmacol; 2006 Sep; 58(3):402-7. PubMed ID: 16416335
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of docetaxel, cisplatin and 5-fluorouracil (DCF) for metastatic esophageal cancer (OGSG 0403).
Tamura S; Imano M; Takiuchi H; Kobayashi K; Imamoto H; Miki H; Goto Y; Aoki T; Peng YF; Tsujinaka T; Furukawa H;
Anticancer Res; 2012 Apr; 32(4):1403-8. PubMed ID: 22493377
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and toxicity of nedaplatin and 5-FU with radiation treatment for advanced esophageal carcinomas.
Kato H; Fukuchi M; Manda R; Nakajima M; Miyazaki T; Sohda M; Masuda N; Fukai Y; Tsukada K; Kuwano H
Anticancer Res; 2003; 23(4):3493-8. PubMed ID: 12926096
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy and safety of biweekly nedaplatin in combination with docetaxel as second-line chemotherapy in patients with unresectable or recurrent esophageal cancer].
Irino T; Egawa T; Kenmochi T; Ito Y; Mihara K; Okamura A; Eto E; Inaba Y; Murakawa M; Nagashima A
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2401-4. PubMed ID: 22202395
[TBL] [Abstract][Full Text] [Related]
39. Concurrent chemoradiotherapy for locally advanced and metastatic esophageal cancer: longterm results of a phase II study of UFT/CDDP with radiotherapy.
Iwase H; Shimada M; Nakamura M; Nakarai K; Iyo T; Kaida S; Indo T; Kato E; Horiuchi Y; Kusugami K
Int J Clin Oncol; 2003 Oct; 8(5):305-11. PubMed ID: 14586756
[TBL] [Abstract][Full Text] [Related]
40. A phase II study of paclitaxel and nedaplatin as first-line chemotherapy in patients with advanced esophageal cancer.
Cao W; Xu C; Lou G; Jiang J; Zhao S; Geng M; Xi W; Li H; Jin Y
Jpn J Clin Oncol; 2009 Sep; 39(9):582-7. PubMed ID: 19509000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
